Phibro Animal Health (PAHC) EBITDA Margin (2012 - 2026)

Phibro Animal Health's EBITDA Margin history runs 15 years deep, the most recent figure standing at 11.64% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 201.0% year-over-year to 11.64%; the TTM figure through Mar 2026 stood at 8.93% (up 461.0% YoY), while the FY2025 annual figure was 8.52%, up 328.0% from the prior year.
• EBITDA Margin was 11.64% for Q1 2026 at Phibro Animal Health, up from 6.72% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 11.64% in Q1 2026 to a low of 2.28% in Q4 2024.
• Historically, EBITDA Margin has averaged 5.83% across 5 years, with a median of 7.55% in 2023.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin plunged 424 bps in 2023, then soared 899 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 4.28% in 2022, then plunged by 76 bps to 1.01% in 2023, then plunged by 326 bps to 2.28% in 2024, then soared by 395 bps to 6.72% in 2025, then jumped by 73 bps to 11.64% in 2026.
• The last three EBITDA Margin figures came in at 11.64% (Q1 2026), 6.72% (Q4 2025), and 8.39% (Q3 2025), per Business Quant data.